

Establishment of Reference Values of Markers of Non-Thyroidal Illness Syndrome on a State-of-the-Art Fully Automated ABEI-Based Chemiluminescence System

Aamir Ijaz¹, Muhammad Usman Anjum², Farhan Ahmed³, Shamila Najeeb Paracha², Farzana Habib²,
Muhammad Bilal Shaukat², Sara Najeeb², Najma Hafeez²

¹NUST School of Health Sciences Islamabad, Pakistan

²Mohi Uddin Islamic Medical College and Hospital Mirpur AJ&K, Pakistan

³Milton-Keyenes University Hospital NHS Trust, Oxford University Hospitals UK

Abstract

Background: Non-Thyroidal Illness Syndrome (NTIS), previously called Euthyroid Sick Syndrome has always been a diagnostic dilemma for Chemical Pathologists and treating physicians. Combination of four test i.e. Reverse Triiodothyronine (rT3), Free Triiodothyronine (fT3), Free Thyroxine (fT4) and Thyroid Stimulating Hormone (TSH) can be helpful to diagnose NTIS in critically ill patients. We need, however, to determine the reference values found in a reference population, free of any thyroidal as well as non-thyroidal illness.

Methods and Materials: Initially, 266 adult volunteers were included in the study from Mohi Uddin Islamic Medical College Mirpur AJ&K (MIMC) and Mohi Uddin Teaching Hospital Mirpur AJ&K (MOTH) after taking written informed consent. About 124 volunteers were selected (males 61; females 63) after exclusion of the volunteers with one or more of the exclusion criteria. Blood specimens were collected and analyzed for rT3, fT3, fT4 and TSH using Maglumi X8 (S nibe, China), an ABEI (N-(aminobutil)-N-(ethyl)-isoluminol) based analyzer at Pathology Laboratory MOTH.

Results: Reference values of rT3, fT3, fT4 and TSH were found to be 13.3 – 19.8 ng/dL (0.2 – 0.30 nmol/L); 2.65 - 4.15 pg/mL (4.08 - 6.39 pmol/L); 10.6 - 16.2 pg/mL (13.64– 20.84 pmol/L) and 0.43 - 3.98 μ IU/mL (0.43 – 3.98 mIU/L), respectively.

Conclusion: Reference values determined in our own population should be used when diagnosing and monitoring NTIS and other thyroid disorders

Keywords: *Reverse Triiodothyronine (rT3), Thyroid Stimulating Hormone (TSH), Free Triiodothyronine (fT3) and Free Thyroxine (fT4)*

Address of Correspondence: Prof Aamir Ijaz, NUST School of Health Sciences Islamabad. email: aamirijaz@nshs.nust.edu.pk

Establishment of Reference Values of Markers of Non-Thyroidal Illness Syndrome on a State-of-the-Art Fully Automated ABEI-Based Chemiluminescence System

Introduction

Non-Thyroidal Illness Syndrome (NTIS), previously called Euthyroid Sick Syndrome is characterized by increased reverse T3 (rT3), and low levels of triiodothyronine (T3), thyroxine (T4) and thyroid-stimulating hormone (TSH) without previous hypothalamic-pituitary dysfunction or preexisting thyroid gland disease¹. Another hallmark of NTIS is complete normalization of these hormones after recovery of the disease that causes the changes². NTIS is a common event in critically ill patients (44-70%)¹. Besides the central regulation of thyroid hormones in the serum by the hypothalamic–pituitary–thyroid (HPT) axis, thyroid concentration inside the cells is tightly controlled by three iodothyronine deiodinase enzymes (DIO1, DIO2 and DIO3), which catalyze the removal of iodine atoms at the outer ring (activation pathway-production of T3) or at the inner ring (inactivation pathway – production of rT3) of T4 and T3³ (Figure 1). The hormonal changes in NTIS (decreased T3 and increased rT3 and rT3/T4) observed during the acute phase of illness are considered beneficial but it is related to the fasting state of the body⁴. Early enteral feeding does not produce these hormonal changes⁵. They may become deleterious during prolonged critical illness, making the stage and severity of illness a major determinant of NTIS⁵. The list of diseases and conditions in which NTIS can occur is quite long and growing e.g. pneumonia, starvation, anorexia nervosa, sepsis, stress, cardiopulmonary bypass, myocardial infarction, malignancies, burns, organ transplantations, hypothermia, inflammatory bowel disease, cirrhosis, major surgery, renal failure, diabetic ketoacidosis⁶, fracture of hip joint⁷, congestive cardiac failure⁸ and COVID-19 infection⁹. There may be unusual variations of thyroid function in some conditions e.g. decrease in the reverse T3 and rT3/T4 ratio, and normal T3 and T3/T4 ratio in HIV¹⁰.

We use the term “reference values” because “normal values” and “reference ranges” are obsolete terms now. There are several different connotations of the term “normal” in statistics, epidemiology and clinical practice¹¹, while the term “range” implies a single value i.e. difference between maximum and minimum values in a distribution¹².

International Federation of Clinical Chemistry (IFCC) has also recommended usage of term “reference values”¹³. Reference values can be determined from a set of large subject or patient data (*posteriori*) or by a pre-planned specimen collection from a reference population after careful exclusion of the disease for which the test is used (*priori*). For less commonly used analytes such as the hormones a priori method is preferable¹⁴. Consideration of biological factors is another important step in reference values studies. The controllable factors are neutralized by standardization of the procedure for preparation of reference individuals and specimen collection, while non-controllable factors such as age and gender become partitioning criteria¹⁵. Three different statistical methods are used for establishment of reference values i.e. non-parametric methods¹⁶ e.g. boot-strap method¹⁷, parametric method¹⁸ and robust method¹⁹. All these methods have their own inherent advantages and limitations²⁰.

Methods and Material

Venue of the Project: Mohi Uddin Islamic Medical College, Mirpur AJ&K, Pakistan (MIMC) and Mohi Uddin Teaching Hospital Mirpur AJ&K, Pakistan (MOTH)

Permission from Institutional Review Board (IRB): Proper permission was obtained from IRB of MIMC.

Study Duration: One year starting from 31st August 2022 to 15th August 2023.

Reference individuals. Two hundred and sixty six volunteers were included in the study, mostly medical students and staff of MIMC and MOTH after taking their informed written consent.

Exclusion criteria

1. Age < 20 years and > 50 years
2. Mild Diseases
3. Participants on any medications
4. Pregnant participants
5. Chronic Illness
6. Thyroid disorders
7. Menstrual irregularities
8. Infertility

Sample Size: A total of 266 volunteers were included in the study for specimen collection. This sample size was used keeping in mind the recommended minimum sample size of minimum 120 individuals for establishing reference values without partitioning for gender and gender²⁰.

Pre-analytical Factors were addressed carefully before blood specimens were collected and analyzed including:

- a. Subject preparation: Volunteers were briefed about the venipuncture to allay their anxiety.
- b. Specimen collection: non-fasting condition, sitting relaxed for about 10 minutes prior to the venipuncture, no double prick and use of fine needles to reduce pain.
- c. Specimen handling: early transport to the lab for centrifugation and serum separation
- d. Specimen Transport: Specimens were immediately transported to the lab
- e. Specimen storage: Stored in an appropriate refrigerator until analyzed

Laboratory Analyses:

- a. After exclusion of the volunteers meeting the exclusion criteria, blood specimens of 124 volunteers were analyzed for four hormones related to NTIS i.e. rT3, fT3, fT4 and TSH.
- b. Chemiluminescence-based autoanalyzer Maglumi-X8 by SNIBE (Shenzhen, China) was used for laboratory based analyses, This, a continuous random access chemiluminescence immunoassay (CLIA) automated system, uses nano-magnetic microbeads separation high throughput (180 tests/h) technology, the luminescence substrate being N-(aminobutyl)-N-(ethyl)-isoluminol (ABEI).
- c. Snibe (Shenzhen China) provided reagents and consumables for this project.
- d. Performance Characteristics of these tests provided by the manufacturers are given in Table 1.
- e. All laboratory results were blinded by allotting unique numbers to the volunteers blood specimens. The lab results of outliers, however, were unblinded for repeating and referral to the related physicians for management.

Quality Control (QC):

- a. Internal QC provided in the reagent kits was run with each batch of analysis
- b. NHS-EQAS[®] was participated to ensure accuracy by inter-laboratory comparison.

Statistical Procedures

1. Non-parametric approach was used for calculation of reference values because of following reasons:
 - a. This is the recommended method by IFCC¹³ and adopted by Clinical and Laboratory Standard Institute (CLSI) of USA²⁰
 - b. The nature of the underlying distribution of the data does not matter.
 - c. No statistical expertise is required; The values obtained from reference individuals were simply put in rank order by concentration (rank 1 is the lowest, rank 2 is the next lowest, etc.).
 - d. The central 95% became the reference interval.
 - e. The 90% confidence limits of the endpoints of the interval was similarly just taken from the data points themselves.
 - f. One hundred and twenty observations provide enough data to determine both the central 95% of the distribution and the 90% confidence limits on both endpoints. That is, with 120 observations, rank 3 is the 2.5th percentile; rank 118 is the 97.5th percentile; ranks 1 and 7 define the 90% confidence interval of the 2.5th percentile; and ranks 114 and 120 define the 90% confidence interval of the 97.5th percentile¹².
2. Since no statistical difference between the two partitioned groups e.g. males and females was found, so separate reference intervals for different partitions were not needed and data was not collected for each partition

Results

One hundred and forty two volunteers were excluded from the study due to falling in one of the exclusion criteria mentioned above (Figure 1). Females (n=41) and Males (n=27) of 20-24 years of age were the most dominant group (Figure 2). Post-analyses exclusion was done for outliers based on Dixon`s Method¹² (0-3 per analyte) (Table 2). Three results of TSH were too high to be included in the data and declared outliers. One participant had high TSH and low fT4 (Primary Hypothyroidism), while in the other two, only TSH was raised (possibly sub-clinical hypothyroidism). All three were referred to the concerned physicians for proper management. Details of the non-parametric procedure used for the determination of lower and upper reference values along with 90% Confidence Limits of

all four hormones are given in Table 2. Table 3 indicates the reference values of 4 hormones in traditional and SI units along with the conversion factors for general utility. In Table 3 we have also compared the reference values determined using Maglumi X8, reference values reported by the manufactures²¹⁻²⁴ and reference values established using Abbott Architect (US)²⁵.

Discussion

This is the first study in Pakistan in which reference values of rT3 has been determined along with other markers of NTIS. The reference values of all four hormones have been compared with reference values determined on another chemiluminescence autoanalyzer i.e. Architect (Abbott)²⁵. Values of TSH of two systems are closest followed by fT3, rT3 and fT4 (Table 3). Except for rT3 reference values reported by the manufacturers (Snibe-China)²¹⁻²⁴ are quite similar to those reported in the present study (Table 3).

rT3 is a unique thyroid hormone which is secreted in an extra-thyroidal site and is used for the exclusion of thyroid diseases²⁶. There has been a close contest in the NTIS literature between rT3 and fT3 as diagnostic markers for NTIS, with fT3 mostly winning the contest of diagnostic marker of NTIS². The probable reasons are easy availability and more consistent decrease of fT3 in NTIS, while rT3 and rT3 / fT3 is increased in most of the cases but may be normal or even decreased in some situations¹⁰. With the advent of better analytical method and equipment (e.g. CLIA and Maglumi by Snibe-China), rT3 is gaining popularity²¹. Moreover, in the presence of central hypothyroidism (pituitary or hypothalamic origin), rT3 will be quite helpful to the physicians. Although role of rT3 in NTIS is questionable, in elderly it has been shown that increased rT3 was the only thyroid hormonal change related to shorter patient survival, with a specificity to predict early death up to 98.5%²⁷. Similarity, decreased fT3, fT4 and TSH have also been reported as effective mortality predictors²⁷.

It is important to note that NTIS has two faces-acute illness and chronic illness²⁸. Divided chronologically, one is good and the other may be bad, depending on the context⁵. A large RCT—the Early versus late Parenteral Nutrition in Critically Ill Adults (EPaNIC) trial—has shown that a macronutrient deficit that occurs in ICU patients during the first week, when only relying on enteral feeding, improves outcomes as compared

with preventing that macronutrient deficit with early initiation of parenteral nutrition²⁹. Moreover, 'early fasting' showed several benefits mediated through hormonal changes of NTIS i.e. increased rT3, decreased fT3, fT4 and TSH e.g. decreased hospital infections, liver abnormalities, muscle weakness, and accelerated recovery³⁰⁻³². It has been implicated that this situation is developed to decrease the metabolic rate of the body and conserve energy⁵. NTIS that occurs in prolonged critically ill patients, who continue to be dependent on intensive medical care for weeks or months, may have a different face, both in its origin and in its impact on outcome^{33,34}.

Another important question is what are the factors which cause the typical hormonal changes seen in NTIS? Previous and going research in this field focuses on pro-inflammatory cytokines. From time to time various cytokines have been implicated e.g. interleukin 6 (IL-6), interleukin 1 β (IL-1 β), soluble interleukin-2 receptor (sIL-2R) and tumor necrosis factor (TNF) α are elevated in septic NTIS patients preceding the decrease in serum T3 and T4^{35,36}. More recently some other cytokines have been found e.g. nuclear factor κ B (NF- κ B) causing LPS-induced deiodinase 2 increase in cell culture^{37,38}. A puzzling feature of NTIS is the absence of increased serum TSH in spite of markedly decreased serum T3 and T4, pointing to altered set-point regulation of the hypothalamus-pituitary-thyroid (HPT) axis. Many possible mechanisms have been reported causing this downregulation e.g. reduced hypothalamic TRH expression and suppression of TRH in the hypothalamic paraventricular nucleus probably mediated by increased local T3 production, resulting from increased DIO2 expression in combination with decreased DIO3 expression in neurons^{39,40}. Treat or not to treat NTIS has been a moot point. Current evidence suggests that NTIS may be a combination of physiologic adaptation and pathologic alteration, with no unifying benefit of treatment with thyroid hormone⁴¹.

In the present study volunteers belonged to all provinces and areas of Pakistan. We will recommend to use these reference values not only in Pakistan but also in surrounding countries and in overseas populations living in other countries.

The instrument we used for analysis of these hormones is the state-of-the-art random access fully automated system (Maglumi X8). CLIA is the ultimate development of time-honored ELISA plate readers, that required immense time and manpower resources with many potential sources of errors⁴².

Conclusion: We have reported reference values of four hormones for use in clinical practice for diagnosing and monitoring of non-thyroidal illness, a very common condition present in critically ill patient.

Recommendation: Facilities for estimation of all these four hormones on a state-of-the-art fully automated ABEI-based chemiluminescence system be made available in hospital laboratories, so that diagnosis and monitoring of NTIS is carried out effectively by the physicians.

Acknowledgement: We are greatly indebted to SNIBE (Shenzhen-China) for providing reagents and consumables for this project and Pakistan Society of Chemical Pathologists (PSCP) for funding this project.

Ethics Statement

- Present article reports portion of the data of a project carried out to facilitate the users of fully automated ABEI-based Chemiluminescence System Maglumi X8.
- By no means we report any comparison of performance of this system with any other system.
- No conflict of interest is declared by the authors, since no comparison of instruments was involved.
- This study was reviewed and approved by the Institutional Review Board of Mohi Uddin Islamic Medical College Mirpur AJ&K, Pakistan.
- Written informed consent of the volunteers was obtained for the study
- To protect privacy of the volunteers all laboratory results were blinded by allotting unique numbers to the blood specimens. The lab results of outliers, however, were unblinded for repeating and referral to the related physicians for management.

References

1. da Silveira CD, de Vasconcelos FP, Moura EB, da Silveira BT, Amorim FF, Shintaku LS, de Santana RB, Argotte PL, da Silva SF, de Oliveira Maia M, Amorim FF. Thyroid Function, Reverse Triiodothyronine, and Mortality in Critically Ill Clinical Patients. *Indian J Crit Care Med.* 2021;25(10):1161-1166. doi: 10.5005/jp-journals-10071-24001. PMID: 34916749; PMCID: PMC8645806.
2. Chopra IJ. Nonthyroidal illness syndrome or euthyroid sick syndrome? *Endocr Pract.* 1996;2(1):45-52. doi: 10.4158/EP.2.1.45. PMID: 15251561.
3. Fliers E, Boelen A. An update on non-thyroidal illness syndrome. *J Endocrinol Invest.* 2021;44(8):1597-1607. doi: 10.1007/s40618-020-01482-4. PMID: 33320308; PMCID: PMC8285315.
4. Sabatino L, Vassalle C, Del Seppia C, Iervasi G. Deiodinases and the Three Types of Thyroid Hormone Deiodination Reactions. *Endocrinol Metab (Seoul).* 2021;36(5):952-964. doi: 10.3803/EnM.2021.1198. Epub 2021 Oct 21. PMID: 34674502; PMCID: PMC8566136.
5. Van den Berghe G. Non-thyroidal illness in the ICU: a syndrome with different faces. *Thyroid.* 2014;24(10):1456-65. doi: 10.1089/thy.2014.0201. Epub 2014 Jun 19. PMID: 24845024; PMCID: PMC4195234.
6. de Vries EM, Fliers E, Boelen A. The molecular basis of the non-thyroidal illness syndrome. *J Endocrinol* 2015;225(3):R67-81. doi: 10.1530/JOE-15-0133. Epub 2015 May 13. PMID: 25972358
7. Cauteruccio M, Vitiello R, Perisano C, Covino M, Sircana G, Piccirillo N, Pesare E, A Ziranu , Maccauro G. Euthyroid sick syndrome in hip fractures: Evaluation of postoperative anemia. *Injury.* 2020;51 Suppl 3:S9-S12. doi: 10.1016/j.injury.2020.07.006. Epub 2020 Jul 3. PMID: 32669206.
8. Okayama D, Minami Y, Kataoka S, Shiga T, Hagiwara N. Thyroid function on admission and outcome in patients hospitalized for acute decompensated heart failure. *J Cardiol.* 2015;66(3):205-11. doi: 10.1016/j.jjcc.2015.04.006. Epub 2015 May 14. PMID: 25982671.
9. Zou R, Wu C, Zhang S, Wang G, Zhang Q, Yu B, Wu Y, Dong H, Wu G, Wu S, Zhong Y. Euthyroid Sick Syndrome in Patients With COVID-19. *Front Endocrinol*

- (Lausanne). 2020;7;11:566439. doi: 10.3389/fendo.2020.566439. PMID: 33117282; PMCID: PMC7575767.
10. Ganesan K, Anastasopoulou C, Wadud K. Euthyroid Sick Syndrome. 2022 Dec 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 29489255.
 11. Kendal MG, Buckland WR. A dictionary of statistical terms, 5th edition. London: Longman; 1990.
 12. Horowitz G, Jones GRD. Establishment and use of reference intervals. In: Rifai N, Horvath AR and Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th Edition. Elsevier. Philadelphia, US. 2018:170-94.
 13. The IFCC recommendations for determining reference intervals: strengths and limitations. J Lab Med 2009;33(2):45–51 2009 by Walter de Gruyter • Berlin • New York. DOI 10.1515/JLM.2009.016
 14. Herbeth B, Henny J, Siest G. Determination of reference values: a priori or a posteriori selection?. Ann Biol Clin (Paris)1986;44(4):411-2. French. PMID: 3789484.
 15. Bjerner J. Age-dependent biochemical quantities: an approach for calculating reference intervals. Scan J Clin Lab Invest 2007;67:707-22.
 16. Linnet K. Non-parametric estimation of reference intervals by simple and bootstrap procedures. Clin Chem 2000;46:867-9.
 17. Corrado Dimauro, Nicolò P.P. Macciotta, Salvatore P.G. Rasso, Cristiana Patta, Giuseppe Pulina, A bootstrap approach to estimate reference intervals of biochemical variables in sheep using reduced sample sizes, Small Ruminant Research2009;83(1–3):34-41.
<https://www.sciencedirect.com/science/article/pii/S0921448809000601>
 18. Kim T, Choi H, Lee SM. Parametric and non-parametric estimation of reference intervals for routine laboratory tests: an analysis of health check-up data for 260 889 young men in the South Korean military. BMJ Open. 2022;12(7):e062617. doi: 10.1136/bmjopen-2022-062617. PMID: 35879016; PMCID: PMC9328105.
 19. Horn PS, Pesce AJ. Reference Intervals: a user's guide, Washington, DC:AACC Press, 2005.

20. Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved Guideline. 3rd ed. Wayne (PA):CLSI; 2008. EP28-A3c.
21. MAGLUMI Rev T3 (CLIA) [Online] Cited on 10th June 2024. Available at: 006 RevT3-IFU-en-EU-V10.3
22. MAGLUMI FT3 (CLIA) [Online] Cited on 10th June 2024. Available at: 003 FT3-IFU-en-EU-V11.1
23. MAGLUMI Free T4 (CLIA) [Online] Cited on 10th June 2024 Available at: 004 FT4-IFU-en-EU-V10.1
24. MAGLUMI TSH (CLIA) [Online] Cited on 10th June 2024. Available at: 005 TSH-IFU-en-EU-V11.1
25. Adeli K, Ceriotti F, Nieuwesteeg M. Reference Information for the Clinical Laboratory. In Rifai N, Horvath AR and Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th Edition. Elsevier. Philadelphia, US. 2018: 1745-89.
26. Luongo C, Dentice M, Salvatore D. Deiodinases and their intricate role in thyroid hormone homeostasis. *Nat Rev Endocrinol*. 2019;15(8):479-488. doi: 10.1038/s41574-019-0218-2. PMID: 31160732.
27. Forestier E, Vinzio S, Sapin R, Schlienger JL, Goichot B. Increased reverse triiodothyronine is associated with shorter survival in independently-living elderly: the Alsanut study. *Eur J Endocrinol*. 2009;160(2):207-14. doi: 10.1530/EJE-08-0519. Epub 2008 Nov 10. PMID: 19001060.
28. Van den Berghe G, de Zegher F, Bouillon R. Acute and prolonged critical illness as different neuroendocrine paradigms. *J Clin Endocrinol Metab* 1998;83:1827–1834.
29. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, Van Cromphaut S, Ingels C, Meersseman P, Muller J, Vlasselaers D, Debaveye Y, Desmet L, Dubois J, Van Assche A, Vanderheyden S, Wilmer A, Van den Berghe G. Early versus late parenteral nutrition in critically ill adults. *N Engl J Med* 2011;365:506–517.

30. Casaer MP, Wilmer A, Hermans G, Wouters PJ, Mesotten D, Van den Berghe G. Role of disease and macronutrient dose in the randomized controlled EPaNIC trial: a post hoc analysis. *Am J Respir Crit Care Med* 2013;187: 247–255.
31. Hermans G, Casaer MP, Clerckx B, Guñiza F, Vanhullebusch T, Derde S, Meersseman P, Derese I, Mesotten D, Wouters PJ, Van Cromphaut S, Debaveye S, Gosselink R, Gunst J, Wilmer A, Van den Berghe G, Vanhorebeek I. Impact of tolerating macronutrient deficit on the development of intensive care unit-acquired weakness. *Lancet Resp Med* 2013;1:621–629.
32. Gunst J, Vanhorebeek I, Casaer MP, Hermans G, Wouters PJ, Dubois J, Claes K, Schetz M, Van den Berghe G. Impact of early parenteral nutrition on metabolism and kidney injury. *J Am Soc Nephrol* 2013;24:995–1005.
33. Van den Berghe G, de Zegher F., Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R, Bowers CY. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. *Clin Endocrinol (Oxf)* 1997;47:599–612.
34. Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. *J Clin Endocrinol Metab* 1997;82:4032–4036.
35. Boelen A, Platvoet-ter Schiphorst MC, Bakker O, Wiersinga WM. The role of cytokines in the lipopolysaccharide-induced sick euthyroid syndrome in mice. *J Endocrinol* 1995;46(3):475–483
36. Boelen A, Maas MA, Lowik CW, Platvoet MC, Wiersinga WM. Induced illness in interleukin-6 (IL-6) knock-out mice: a causal role of IL-6 in the development of the low 3,5,3'-triiodothyronine syndrome. *Endocrinology* 1996;137(12):5250–5254
37. de Vries EM, Kwakkel J, Eggels L, Kalsbeek A, Barrett P, Fliers E, Boelen A. NFkappaB signaling is essential for the lipopolysaccharide-induced increase of type 2 deiodinase in tanycytes. *Endocrinology* 2014;155(5):2000–2008. <https://doi.org/10.1210/en.2013-2018>

38. de Vries EM, Nagel S, Haenold R, Sundaram SM, Pfrieder FW, Fliers E, Heuer H, Boelen A. The role of hypothalamic NF-kappaB Signaling in the response of the HPT-Axis to acute inflammation in female mice. *Endocrinology* 2016;157(7):2947–2956. <https://doi.org/10.1210/en.2016-1027>
39. Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. *J Clin Endocrinol Metab* 1997;82(12):4032–4036
40. de Vries EM, Surovtseva O, Vos WG, Kunst RF, van Beeren M, Kwakkel J, Chassande O, Ackermans MT, Fliers E, Boelen A. Downregulation of Type 3 deiodinase in the hypothalamus during inflammation. *Thyroid* 2019;29(9):1336–1343. <https://doi.org/10.1089/thy.2019.0201>
41. Lee S, Farwell AP. Euthyroid Sick Syndrome. *Compr Physiol*. 2016;15;6(2):1071-80. doi: 10.1002/cphy.c150017. PMID: 27065175.
42. Kricka LJ, Park JY. Principles of Immunochemical Techniques. In: Burtis CA, and Bruns DE, eds. *Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics*. 6th Edition. SAUNDERS (Elsevier). Philadelphia, US. 2018:361-3.

Figure 1: Positions of Iodine Atoms in Thyroid Hormones

Figure 2: Distribution of Volunteers Excluded from Study (n = 142)

Figure 3: Age and Gender Distribution of Selected Volunteers (n = 124)

Table 1: Performance Characteristics of NTIS Related Hormones

Name of Hormone	Precision (Intra-assay) CV%	LOB & LOD	Analytical Specificity (Cross reactivity)	AMR	Linearity	Method Comparison
Reverse T3 ²¹	4.88%	5 & 10 ng/dL	None	5 – 100 ng/dL	r=0.997	y=0.985x + 0.007
Free T3 ²²	4.63%	0.2 & 0.4 pg/mL	T4: <0.01% T3: <0.01 %	0.2 – 50 pg/mL	r=0.9506	y= 0.970x + 0.02338
Free T4 ²³	4.24%	1.0 & 1.5 pg/mL	T4: <0.01% T3: <0.01 %	1.0 – 120 pg/mL	r=0.997	y= 1.019x + 0.442
TSH ²⁴	2.53%	0.001 & 0.006 mIU/L	None	0.001 – 100 mIU/L	r=0.9596	y=0.953x + 0.327

**Table 2: Non-Parametric Determination of Reference Values of NTIS
Related Hormones¹²
(Number of Blood Specimen Analyzed = 124)**

Name of Hormone	Outliers	Rank No of Percentile		Original Value Corresponding to the Rank Number		90% Confidence Limits (90%CL)		Summary	
		Lower: 0.025	Upper: 0.975	Lower Limit (2.5 percentile)	Upper Limit (97.5 percentile)	Lower Reference Limits Rank #	Upper Reference Limits Rank# (n+1)-7 & (n+1)-1	Lower Limit (90% CL)	Upper Limit (90% CL)
Reverse T3	0	0.025 x (124+1) = 3.125 i.e. #3	0.0975 x (124+1) = 121.875 i.e. #122	13.3 ng /dL	19.8 ng /dL	#1 and #7 Values: 12.1 & 14.7 ng/dL	#118 & #124 Value:18.5 & 20.9 ng/dL	13.3 (12.1 and 14.7) ng/dL	19.8 (18.5 and 20.9) ng/dL
Free T3	0	0.025 x (124+1) = 3.125 i.e. #3	0.0975 x (124+1) = 121.875 i.e. #122	2.65 pg/mL	4.15 pg/mL	#1 and #7 Values: 0.98 & 2.65 pg/mL	#118 & #124 Value: 3.98 & 4.48 pg/mL	2.65 (2.48 and 2.7) pg/mL	4.15 (3.98 and 4.48) pg/mL
Free T4	1	0.025 x (123+1) = 3.1 i.e. #3	0.0975 x (123+1) = 120.9 i.e. #121	10.6 pg/mL	16.2 pg/mL	#1 and #7 Values: 10.1 & 11.3 pg/mL	##117 & #123 Value: 15.7 & 16.5 pg/mL)	10.6 (10.1 and 11.3) pg/mL	16.2 (15.7 & 16.5) pg/mL
TSH	3	0.025 x (121+1) = 3.05 i.e. #3	0.0975 (121+1) = 118.95 i.e. #119	0.43 mIU/L	3.98 mIU/L	#1 and #7 Values:0.31& 0.76 mIU/L	#115 & #121 Value: 3.82 & 4.12 mIU/L	0.43 (0.31 and 0.76) mIU/L	3.98 (3.82 & 4.12) mIU/L

Table 3: Reference Values NTIS Related Hormones Determined by Different Systems in Traditional and SI Units				
Name of Hormone	Reference Values Reported in Present Study	Reference Values Reported by Manufacturer	Reference Values Reported on Abbot Architect	Conversion Factor (Traditional to SI Units)
Units (SI Units)	On Maglumi X8 (SNIBE) Traditional Units (SI Units)	On Maglumi X8 (SNIBE) Traditional Units (SI Units) ²¹⁻²⁴	Traditional Units (SI Units) ²⁵	
Reverse T3 ng/dL (nmol/L)	13 – 19 (0.2 – 0.29)	31 – 95 (0.48 – 1.46)	10 – 28 (0.15 – 0.43)-	ng/dL to nmol/L X 0.0154
Free T3 pg/mL (pmol/L)	2.65 - 4.15 (4.08 - 6.39)	2.0 – 4.2 (1.86 – 6.43)	2.1 – 4.4 (3.23 – 6.77)	pg/mL to pmol/L X 1.54
Free T4 pg/mL (pmol/L)	10.6 - 16.2 (13.64– 20.84)	8.9-17.2 (11.4 - 22.13)	8 – 27 (10.3 – 34.7)	pg/mL to pmol/L X 1.287
TSH μIU/mL (mIU/L)	0.43 - 3.98 (0.43 – 3.98)	0.3-4.5 (0.3-4.5)	0.4 – 4.2 (0.4 – 4.2)	μIU/mL to mIU/L X 1

Figure 1: Positions of Iodine Atoms in Thyroid Hormones





Figure 2: Distribution of Volunteers Excluded from Study (n = 142)



Figure

Figure 3: Age and Gender Distribution of Selected Volunteers (n = 124)

